Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers

This is a Phase II, single arm study looking at the rate of major clinical response and non-operative management in Stage II and III colon cancer after 18 weeks (up to 6 cycles) of neoadjuvant dostarlimab.

Trial Details

NCT ID
NCT05239546
Phase
PHASE2
Sponsor
University of Iowa
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Dostarlimab
Locations (sample)
  • Iowa City, Iowa, United States|41.66113,-91.53017
  • Madison, Wisconsin, United States|43.07305,-89.40123

Key Eligibility Criteria

  • Capable of understanding and complying with the protocol requirements and have signed the informed consent document. Patients with mild cognitive i…
  • 18 years or older in age
  • Biopsy proven dMMR (by IHC), Stage II or III colon cancer per CT imaging correlation with AJCC 8th edition, 2017, amendable to en block surgical re…
  • Biopsy specimen for diagnosis of dMMR Colon cancer should have enough tissue for minimum 4 and max 6 adjacent unstained FFPE slides (4µm each) as d…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →